Lexicon Pharmaceuticals Shifts Focus to Clinical Development Following Zynquista Setbacks

Lexicon Pharmaceuticals, Zynquista, FDA, Clinical Development, Restructuring, R&D Pipeline, LX9211, Sotagliflozin, LX9851

Lexicon Pharmaceuticals Shifts Focus to Clinical Development Following FDA Setbacks

Lexicon Pharmaceuticals, FDA setbacks, Clinical development focus, Commercial operations elimination, Sotagliflozin, Type 1 diabetes, Chronic kidney disease, Restructuring